Introduction

Hypoglycemic agents for the treatment of type 2 diabetes mellitus have a limited time effectiveness. A new hypoglycemic peptide is proposed with antioxidant action, which stimulates insulin and glp-1 secretion. The pre-clinical, preliminary data, demonstrates an effectiveness of ~ 70%. This molecule may be the first of a new class of hypoglycemic drugs.

Technical features

Treatment with the peptide molecule stimulates:

1) insulin secretion from insulinoma cells and human langerhans islets, independently from hyper or hypoglycemia;

2) the release of Glp-1 from immortalized intestinal cells (like-cells).

Furthermore, in pre-clinical studies this molecule decreases the levels of insulin-resistance, suggesting also an effect on the chronic complications of diabetes mellitus.

 

Possible Applications

• Hypoglicemic drug for the treatment of type 1 and 2 dm;
• Prevention and cure (p/c) of diabetic micro and macrovascular complications;
• P/c of diabetic retinopathy;
• P/c of diabetic neuropathy;
• P/c of diabetic nephropathy;
• P/c of obesity.

Advantages

• Prevention of diabetes mellitus, its complications and obesity;
• Association with other therapies;
• Stimulates glucose-independent insulin secretion;
• Promotes Glp-1 release;
• Modulation of Glp-1-dependent insulin secretion;
• Reduction of oxidative stress and insulin resistance levels.